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Philadelphia, Pennsylvania
Several trends have been rapidly evolving in both cardiology
and health care policy that will soon pose difficult choices
for the physician. On the one hand, in addition to the pan-
oply of currently available diagnostic techniques, exciting
new modalities such as nuclear magnetic resonance imaging
and ultrafast computed axial tomography are becoming ap-
plicable for diagnosis and evaluation of heart disease. Ther-
apeutic techniques such as percutaneous transluminal coro-
nary angioplasty (PTCA), and possibly laser angioplasty in
the near future, are increasingly being employed for patient
care. On the other hand, health care policy has become cost
containment oriented so that only those procedures neces-
sary for optimal medical care will be utilized (1-3). Faced
with ever increasing new technologies and the constraints
of cost containment, how will the practicing cardiologist
provide high quality care without coming into conflict with
the new economic realities (4-6)?
The Problem
To those of us who are responsible for making patient
care decisions every day, the possibility that pressures out-
side the physician-patient relation could affect management
strategy and limit our clinical judgment seems both threat-
ening and potentially harmful to our patients. Nevertheless,
because these pressures are current reality, it is imperative
that we define what constitutes optimal medical care with
minimal expense. Strategies should be elucidated that are
less costly but as effective as commonly used strategies,
only if and when these can be identified. In addition, any
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policy must be flexible enough in its application to take into
account physician judgments of individual patient differ-
ences.
In this regard, Rapaport (7) has suggested better edu-
cation of physicians in training, the ordering of only one of
several tests yielding measurements of a single variable and
the elimination of screening tests with a large number of
false positive results. In addition, although many tests yield
valid information, the results often do not have a significant
influence on patient management (8). Conversely, recent
large scale multicenter studies have identified subsets of
patients who are at high risk on the basis of such tests. It
has become apparent that the provision of optimal care in-
cludes the employment of those tests that will identify not
only patients with disease but, in particular, those at high
risk.
Suggested Principles for Ordering
Diagnostic Tests
When ordering diagnostic tests, several additional prin-
ciples must be kept in mind (9-I3): 1) Sensitivity and spec-
ificity as such characterize a test and are useful clinically
in determining the probability of disease only if the pretest
likelihood of disease is known. 2) Predictive value, that is,
the probability of disease being present if the test is positive
(and vice versa if the test is negative), is the most important
clinical variable. 3) Tests with low specificity have by def-
inition a high incidence of a positive result in patients with-
out disease and therefore result in unnecessary additional
tests. An example of this may be radionuclide angiography
to diagnose coronary artery disease in patients with an ab-
normal left ventricle due to another disease. 4) There is no
need to order two tests that measure the same variable, such
as both an echocardiogram and radionuclide angiogram to
evaluate left ventricular performance in uncomplicated cases.
In the patient being evaluated for uncomplicated coronary
artery disease, although the rest and exercise radionuclide
angiographic ejection fraction have demonstrable diagnostic
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and prognostic value, no such data are currently available
for echocardiography. Therefore, there appears to be no
rationale for routine echocardiography in the evaluation of
these patients. 5) Studies should not be ordered unless the
test result will influence management. For example, because
the role of antiarrhythmic therapy in preventing sudden death
is questionable in patients with chronic stable angina, am-
bulatory electrocardiographic (ECG) monitoring would not
be justifiable in the routine evaluation of such patients.
To assure that quality care and cost containment do not
become mutually exclusive, clarity of goals in ordering tests
will be mandatory. In stable patients, the cardiologist must
basically answer three major questions before deciding on
therapy: I) does the patient have disease; 2) what is the
prognosis; and 3) can this prognosis be modified by changing
therapy? Coronary artery disease may be a good example
to evaluate from this point of view because, by virtue both
of the large number of patients and the expense of the tests
employed, this disease represents a very high cost to the
health care system.
Diagnosis of Coronary Artery Disease
It is now quite clear that a well taken history in assessing
chest pain is by far the best "diagnostic test" in predicting
the presence or absence of coronary artery disease (9, 10),
particularly when age, sex and risk factors are added. On
the basis of this assessment, an informed estimate of the
likelihood of coronary disease can be made that is highly
relevant to the need for ordering additional diagnostic tests
(11). Subsequent sequential test analysis by Bayes' theorem
indicates that further noninvasive tests are useful in estab-
lishing or ruling out coronary artery disease only when the
pretest likelihood is in the 50% range (12). Noninvasive
testing is of little real benefit when "pretest probability" is
either high or low (9,13-16). This approach requires that
physicians and patients find acceptable knowledge of the
probability (rather than the certainty) of the presence of
coronary artery disease, particularly when indexes of prog-
nosis are good (see later). Thus, it is crucial that a decision
first be made as to how important it is to exclude coronary
artery disease entirely, because only coronary angiography
can absolutely rule in or rule out this diagnosis.
These principles have direct applicability to patient man-
agement (13). For example, a middle-aged man with the
typical chest discomfort of angina pectoris and known risk
factors has a very high probability of coronary artery dis-
ease. No additional diagnostic value would be obtained from
noninvasive testing because the result, whether positive or
negative, would not substantially change this probability
(9,14) (of course, there may be prognostic value of such
testing as discussed later). Conversely, a young woman with
atypical chest pain and no risk factors has a clinically in-
significant probability of having coronary artery disease that
would be raised only slightly by a positive noninvasive test
because there is a high incidence of false positive tests in
this group. These patient examples also illustrate the phy-
sician's need to assess the requirement for a definitive di-
agnosis; it is probably not indicated to perform coronary
angiography in the young woman cited because her prog-
nosis is excellent even if coronary artery disease is found,
whereas the middle-aged man with several risk factors may
be at higher risk, and the diagnosis must be established.
Which stress test or tests are most useful for diagnosis
in patients with an unclear diagnosis. such as those with
"atypical angina" (15-19)? Specifically, should a stress
nuclear scan be routinely ordered as the initial test in as-
sociation with a stress ECG given the small, albeit definite,
improvement in diagnostic accuracy (19-23)? Certainly,
such an approach is warranted whenever the baseline ECG
is markedly abnormal or when other conditions (for ex-
ample, digitalis administration) suggest that the ECG inter-
pretation will be of limited value in a specific patient. This
may become an important issue in a cost containment en-
vironment.
Assessment of Prognosis
Once the diagnosis of coronary artery disease is estab-
lished with reasonable certainty, an assessment of prognosis
is essential to determine optimal treatment and changes in
life-style, because it is clear that prognosis can be favorably
affected in certain patient subsets (24,25). It is well known
that patients with stable disease have the poorest prognosis
if they have significant left ventricular dysfunction as well
as significant left main coronary artery obstruction or three
vessel disease, or both. In addition, the Coronary Artery
Surgery Study (CASS) (24) and the European Coronary
Surgery Study Group (25) have identified that in these spe-
cific patient groups coronary artery bypass surgery is likely
to improve prognosis. Furthermore, and regardless of left
ventricular function, patients with a proximal left anterior
descending coronary occlusion and additional three vessel
disease have a particularly poor prognosis (26) that may
improve with appropriate intervention.
The usefulness of noninvasive testing in predicting se-
verity and prognosis of coronary artery disease is well es-
tablished. Currently, the stress ECG, radionuclide angi-
ography and thallium imaging have all been shown to be
of prognostic value in patients with stable coronary artery
disease and after acute myocardial infarction. A positive
stress ECG predicts an increased likelihood of subsequent
coronary events over a 4 year follow-up; patients with a
normal test have a 7% rate of events compared with 46%
for those with a positive test (27). Similarly, low level stress
testing after a myocardial infarction has been shown to pre-
dict with a high degree of certainty those patients at risk
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for recurrent events (28-31); patients with a negative test
have only a 3% I year mortality rate compared with a 19%
I year mortality rate in those with a positive test (28-31).
Thus, early identification of patients as belonging to a high
risk subgroup potentially leads to early intervention and has
a substantial impact on outcome.
Role of Coronary Arteriography
Becausecoronary angiography is currently the only method
that will provide unequivocal diagnostic and prognostic in-
formation, should it be performed routinely for diagnosis?
In our view, this is unnecessary and inappropriate in view
of both the cost and risk of the procedure. Currently, ar-
teriography is indicated in patients who have 1) conflicting
noninvasive test results that leave the diagnosis uncertain,
as discussed previously; 2) significant and medically un-
controllable chest pain or potentially unstable symptoms,
or both; and 3) mild, stable symptoms but evidence sug-
gesting severe coronary heart disease and therefore a poor
prognosis. Patients in these three categories would all be
suitable candidates for coronary angiography to establish
the diagnosis in group I and for surgical or angioplasty
consideration in groups 2 and 3.
Having suggested the above guidelines, it is vital to main-
tain a flexible approach, and to keep the principles of di-
agnostic testing firmly in mind. For example, the indications
for coronary angioplasty are rapidly expanding and, al-
though its ultimate role is speculative, its increasing utili-
zation in patients who otherwise would not be considered
candidates for bypass surgery may substantially alter the
indications for coronary angiography. In addition, the role
of soon to be available diagnostic techniques in the evalu-
ation of patients with suspected coronary artery disease is
undefined at present.
Potential Role of Newer Modalities
Both positron emission tomograph y and tomographic
thallium imaging have been studied by some institutions to
determine their efficacy in evaluating patients with coronary
artery disease. Positron emission tomography has the ad-
vantage of very rapid acquisition and the ability to perform
sequential studies after various maneuvers because of the
rapid half-life of the isotopes used (32). Tomographic thal-
lium imaging is possibly a more accurate and quantitative
technique to assess the size of perfusion defects as compared
with routine thallium scans (33). The major disadvantage
of positron emission tomography is its expense, because it
requires a separate building and an on-site generator of
positron emitters because of the very rapid positron-emitting
radiopharmaceutical half-life. However, tomographic thal-
lium imaging is less costly, and could replace conventional
thallium imaging if its diagnostic and prognostic accuracy
proves clearly superior.
The use of nuclear magnetic resonance imaging for car-
diac diagnosis is widely recognized to hold vast potential
(34,35). Recently, cardiac gating techniques have been used
to control magnetic resonance imaging pulse sequence tim-
ing, which allows the acquisition of both anatomic and
functional data. The transverse views are excellent in re-
vealing anatomic myocardial and chamber abnormalities.
Furthermore, becauseblood flow ordinarily producesa weak
signal, structural features of the large arteries are well dis-
played. It is therefore possible that images of the coronary
anatomy (including areas of obstruction) can be produced.
In addition, nuclear magnetic resonance imaging has great
promise for direct tissue characterization, blood flow mea-
surements and assessment of myocardial metabolism. It is
premature to speculate on the degree to which nuclear mag-
netic resonance imaging will supplant currently available
techniques, because the degree to which it will enhance
morphologic, functional and tissue characterization is un-
known.
Experience with the traditional 2 to 5 second body com-
puted tomographic scanner has shown that clinically useful
information is obtainable regarding a number of cardiovas-
cular conditions, including coronary artery bypass graft pat-
ency, intracardiac thrombosis, cardiac tumors, pericardial
disease and aortic dissection. In ultrafast computed tomo-
graphic scanning, image acquisition can be performed at a
rate of 17 scans/s and by gating acquisition to the ECG,
evaluations of blood flow by time-density curves and left
ventricular function at rest and during exercise can be ob-
tained, as can measurement of myocardial mass. There is
also promise in the estimation of regional myocardial blood
flow, pulmonary perfusion, coronary bypass graft flow and
myocardial infarct size. Thus, ultrafast computed tomog-
raphy may have the capacity to perform several diagnostic
functions.
Unfortunately , the expense ofboth nuclear magnetic res-
onance imaging and ultrafast computed tomography cur-
rently is considerable . In this era of cost containment, the
utilization of these modalities, therefore, will be judged
largely by what they add to diagnostic and prognostic ac-
curacy when compared with current testing. Otherwise, one
could envision the cost of a patient undergoing coronary
arteriography (using a digital subtraction angiographic sys-
tem) to definecoronary anatomy; radionuclide angiography,
ultrafastcomputed tomography, nuclear magnetic resonance
imaging, echocardiography and digital subtraction ventric-
ulography in some combination to evaluate global and re-
gional left ventricular function; positron emission tomog-
raphy or tomographic thallium imaging for perfusion; and
nuclear magnetic resonance imaging for metabolic studies
and for tissue characterization. Conversely, nuclear mag-
netic resonance imaging or fast computed tomography, or
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both. may prove to be quite useful if the information gained
through their use leads to a strategy that results in a sig-
nifi cant decrease in mortality and avoids costs incurred over
time from a less effective medical therapy. However, the
depiction of morphology and function, as well as even myo-
cardial perfusion. myocardial metabolism and myocardial
tissue characterization, would not suffice to justify these
very costly tests unless they ultimately can be shown to
favorably affect " health outcome." It may turn out that
coronary angiography alone is the most effective manage-
ment strategy.
Reimbursement is under increasing scrutiny by both the
private sector and the federal government for both new and
well established and widely used diagnostic tests. The use
of current "standard" and newer tests must be efficient,
rational and justifiable as demonstrably influencing patient
management. The requirement for such justifi cation before
ordering a test need not be regarded solely as bad news.
Perhaps the physician can use this constraint as a stimulus
to clearer thinking and better judgment.
Conclusion
Regardless of our feelings about this new environment,
it is imperative that as physicians we assume responsibility
for setting guidelines and standards that would lead to more
efficient. streamlined and improved patient care. We must
take the lead in defining optimal healthcare in which benefits
are expressed in terms of health outcomes, rather than al-
lowing decisions to be made by " cost-benefi t analysis," in
which costs and benefits are valued solely in monetary terms,
Through our specialty societies in cardiology, we must set
standards for appropriate care and develop communication
with both cost-conscious payers and the public. Failure to
do so may result in a new and potentially major risk factor
for patients: loss of the physician's prerogatives in diag-
nostic evaluation and the delivery of optimal care.
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